Halozyme Therapeutics Inc.
NASDAQ:HALO
| Market Cap (Intraday) | 6.79B |
| Current PE | 14.00 |
| Forward PE | 10.4 |
| 2yr Forward PE | 7.66 |
| 10-Day MA | $56.54 |
| 50-Day MA | $55.13 |
| 200-Day MA | $55.41 |
Halozyme Therapeutics Inc. Stock, NASDAQ:HALO
12390 El Camino Real, San Diego, California 92130
United States of America
Phone: +1.858.794.8889
Number of Employees: 350
Description
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.